The case for & against
Bull & Bear analysis
Bullish
Exagen Inc. (NASDAQ: EXGN) is an emerging commercial-stage diagnostics company that specializes in autoimmune disease testing. The company positions itself as a leader in the diagnostics market with its proprietary AVISE® testing platform, which aids in diagnosing and managing conditions such as lupus and rheumatoid arthritis. Exagen operates in a growing market, with an estimated size of $2.2 billion expected to expand at an annual rate of 5%. The firm’s commitment to innovative biomarker solutions highlights its strategic focus on enhancing clinical decision-making and addressing significant gaps in patient care.
Bull says
- ↑Q2 revenue of $19.9M up 16% YoY
- ↑2026 revenue guidance lifted to $72–75M from $70–73M
- ↑Q2 gross margin improved 90 bp YoY to 61%, targeting mid-60s
- ↑Cash balance of $22M supports liquidity and growth investment
- ↑New biomarkers pipeline (myositis roll-out in early 2027)
- ↑Manageable leverage and solid liquidity underpin expansion
Bear says
- ↓Negative earnings yield underscores lack of profitability
- ↓ASP growth slowing amid reimbursement negotiations
- ↓Q2 operating expenses of $13M consume 65% of revenue
- ↓Seasonal Q3/Q4 slowdown could weigh on volume growth
- ↓Revenue cycle management volatility may affect collections
- ↓Low profitability factors and elevated volatility risk
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-05-2026bullish
Transcript signals
Bull points
- we don't guide volume on a quarter-by-quarter basis, but the way we think about it is we had a fantastic Q2, and that was, you're right, Q2 tends to be our best quarter of the year, but this outperformed what we've seen in terms of historical performance.
- As we discussed during the last earnings call, we refinanced our debt and added additional tranches that we can utilize at our option.
- we delivered $17.2 million in the second quarter, a 14% increase over 2024. And this growth came from an increase in volume, which was up 14% sequentially from the first quarter and 7% from the second quarter of 2024, as well as continued ASP expansion.
Bear points
- So we had a net addition of two territories.
- Our net loss for the second quarter is $4.4 million compared to $3 million in the same period last year. The most significant drivers of this change being the impact of our new debt facility, which added $600,000 in non-cash interest and fair value adjustments, $300,000 for loss on debt extinguishment, and $400,000 in cash interest expense.
- Adjusted EBITDA loss was 1.7 million in the first quarter versus 1.6 million in the second quarter of 2024.
Read full transcript analysis ›